Azacitidine and Dapsone drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Azacitidine (azacitidine) and Dapsone (dapsone). Common drug interactions include blood bilirubin increased among females and acute febrile neutrophilic dermatosis among males.

The phase IV clinical study analyzes what interactions people have when they take Azacitidine and Dapsone. It is created by eHealthMe based on reports of 15 people who take the same drugs from the FDA, and is updated regularly.

What is Azacitidine?

Azacitidine has active ingredients of azacitidine. eHealthMe is studying from 17,184 Azacitidine users. Check the latest studies of Azacitidine.

What is Dapsone?

Dapsone has active ingredients of dapsone. It is often used in dermatitis herpetiformis. eHealthMe is studying from 11,732 Dapsone users. Check the latest studies of Dapsone.



On Jul, 12, 2026

15 people who take Azacitidine and Dapsone together, and have interactions are studied.

Azacitidine and Dapsone drug interactions.

What are the common drug interactions of Azacitidine and Dapsone, by gender? *:

female:

  1. Blood bilirubin increased
  2. Epiglottitis (inflammation of the epiglottis)
  3. Intestinal perforation (complete penetration of the wall of the intestine)
  4. Pneumonia
  5. Pyrexia (fever)
  6. Rash
  7. Blood phosphorus decreased
  8. Disease progression
  9. Drug ineffective
  10. Muscle spasms (muscle contraction)

male:

  1. Acute febrile neutrophilic dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender)
  2. Ill-defined disorder
  3. Pulmonary oedema (fluid accumulation in the lungs)
  4. Atrial fibrillation (fibrillation of the muscles of the atria of the heart)
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Encephalopathy (functioning of the brain is affected by some agent or condition)
  7. Fatigue (feeling of tiredness)
  8. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  9. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  10. Hepatic failure (liver failure)

What are the common drug interactions of Azacitidine and Dapsone, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Disease progression
  2. Drug ineffective
  3. Myelosuppression (a decrease in the production of blood cells)
  4. Neutrophil count decreased (less than normal number of neutrophil a type of blood cell)

50-59:

  1. Blood phosphorus decreased
  2. Muscle spasms (muscle contraction)
  3. Muscle twitching

60+:

  1. Pneumonia
  2. Confusional state
  3. Pyrexia (fever)
  4. Rash
  5. Sepsis (a severe blood infection that can lead to organ failure and death)
  6. Encephalopathy (functioning of the brain is affected by some agent or condition)
  7. Fatigue (feeling of tiredness)
  8. Gastroenteritis viral (inflammation of stomach and intestine caused by virus infection)
  9. Graft versus host disease (the donated bone marrow or stem cells view the recipient's body as foreign, and the donated cells/bone marrow attack the body)
  10. Hepatic failure (liver failure)

What are the existing conditions these people have? *

  1. Myelodysplastic Syndrome (a group of conditions that occur when the blood-forming cells in the bone marrow are damaged): 7 people, 46.67%
  2. Polychondritis (progressive inflammation of cartilage and other connective tissue): 4 people, 26.67%
  3. Acute Febrile Neutrophilic Dermatosis (skin disease characterized by the sudden onset of fever, leukocytosis, and tender): 3 people, 20.00%
  4. Acute Myeloid Leukaemia (acute cancer in which the bone marrow makes abnormal myeloblasts): 3 people, 20.00%
  5. Pain: 2 people, 13.33%
  6. T-Cell Lymphoma (a blood cell cancer): 1 person, 6.67%
  7. Chronic Myelomonocytic Leukaemia (cancers of the blood-forming cells of the bone marrow): 1 person, 6.67%
  8. Acute Myeloid Leukaemia Recurrent (acute cancer in which the bone marrow makes abnormal myeloblast- recurrent): 1 person, 6.67%
  9. Adrenal Insufficiency (a condition in which the adrenal glands do not produce adequate amounts of steroids): 1 person, 6.67%
  10. Allergic Rhinitis: 1 person, 6.67%

* Approximation only. Some reports may have incomplete information.

Do you take Azacitidine and Dapsone?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Azacitidine and Dapsone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Azacitidine:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Dapsone:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Azacitidine and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Dapsone and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies


How the study uses the data?

The study uses data from the FDA. It is based on azacitidine and dapsone (the active ingredients of Azacitidine and Dapsone, respectively), and Azacitidine and Dapsone (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: